Developing innovative therapies for kidney disease patients in Greater China
SanReno Therapeutics is a joint venture spun out of Chinook Therapeutics to develop and commercialize kidney disease therapies that address significant unmet needs for patients in Greater China. The company’s lead assets are atrasentan and BION-1301, both in clinical trials for IgA nephropathy.
